KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBT (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of EBT data on record, last reported at $153.6 million in Q2 2025.

  • For Q2 2025, EBT rose 1031.6% year-over-year to $153.6 million; the TTM value through Jun 2025 reached $280.9 million, down 6.66%, while the annual FY2024 figure was $168.7 million, 159.93% up from the prior year.
  • EBT reached $153.6 million in Q2 2025 per SRPT's latest filing, up from $79.6 million in the prior quarter.
  • Across five years, EBT topped out at $337.3 million in Q4 2022 and bottomed at -$512.7 million in Q1 2023.
  • Average EBT over 5 years is -$37.0 million, with a median of -$33.2 million recorded in 2023.
  • Peak YoY movement for EBT: crashed 863.3% in 2021, then surged 1031.6% in 2025.
  • A 5-year view of EBT shows it stood at -$121.9 million in 2021, then soared by 376.71% to $337.3 million in 2022, then dropped by 17.27% to $279.0 million in 2023, then tumbled by 71.46% to $79.6 million in 2024, then soared by 92.93% to $153.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $153.6 million in Q2 2025, $79.6 million in Q4 2024, and $34.0 million in Q3 2024.